Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A2 based on a 1,3-disubstituted propan-2-one skeleton

被引:79
作者
Connolly, S
Bennion, C
Botterell, S
Croshaw, PJ
Hallam, C
Hardy, K
Hartopp, P
Jackson, CG
King, SJ
Lawrence, L
Mete, A
Murray, D
Robinson, DH
Smith, GM
Stein, L
Walters, I
Wells, E
Withnall, WJ
机构
[1] AstraZeneca R&D Charnwood, Dept Med Chem, Loughborough LE11 5RH, Leics, England
[2] AstraZeneca R&D Charnwood, Dept Mol Biol, Loughborough LE11 5RH, Leics, England
[3] AstraZeneca R&D Charnwood, Dept Discovery BioSci, Loughborough LE11 5RH, Leics, England
关键词
D O I
10.1021/jm011050x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Using knowledge of the substrate specificity of cPLA(2) (phospliolipases A(2)), a novel series of inhibitors of this enzyme were designed based upon a three point model of inhibitor binding to the enzyme active site comprising a lipophilic anchor, an electrophilic serine "trap", and an acidic binding moiety. The resulting 1,3-diheteroatom-substituted propan-2-ones were evaluated as inhibitors of cPLA2 in both aggregated bilayer and soluble substrate assays. Systematic variation of the lipophilic, electrophilic, and acidic groups revealed a well-defined structure-activity relationship against the enzyme. Optimization of each group led to compound 22 (ARC70484XX), which contains a decyloxy lipophilic side chain, a 1,3-diaryloxypropan-2-one moiety as a unique serine trap, and a benzoic acid as the acidic binding group. AR-C70484XX was found to be among the most potent in vitro inhibitors of cPLA2, described to date being more than 20-fold more active against the isolated enzyme (IC50 = 0.03 muM) than the standard CPLA(2) inhibitor, arachidonyl trifluoromethyl ketone (AACOCF(3)), and also greater than 10-fold more active than AACOCF3 against the cellular production of arachidonic acid by HL60 cells (IC50 = 2.8 muM).
引用
收藏
页码:1348 / 1362
页数:15
相关论文
共 54 条
[1]  
AYSCOUGH A, 1995, EXPERT OPIN THER PAT, V5, P653
[2]  
BARTOLI F, 1994, J BIOL CHEM, V269, P15625
[3]   DISCOVERY OF NEW NON-PHOSPHOLIPID INHIBITORS OF THE SECRETORY PHOSPHOLIPASES A(2) [J].
BEATON, HG ;
BENNION, C ;
CONNOLLY, S ;
COOK, AR ;
GENSMANTEL, NP ;
HALLAM, C ;
HARDY, K ;
HITCHIN, B ;
JACKSON, CG ;
ROBINSON, DH .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (05) :557-559
[4]   DESIGN AND SYNTHESIS OF SOME SUBSTRATE-ANALOG INHIBITORS OF PHOSPHOLIPASE-A2 AND INVESTIGATIONS BY NMR AND MOLECULAR MODELING INTO THE BINDING INTERACTIONS IN THE ENZYME-INHIBITOR COMPLEX [J].
BENNION, C ;
CONNOLLY, S ;
GENSMANTEL, NP ;
HALLAM, C ;
JACKSON, CG ;
PRIMROSE, WU ;
ROBERTS, GCK ;
ROBINSON, DH ;
SLAICH, PK .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (16) :2939-2951
[5]   Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A(2) [J].
Bonventre, JV ;
Huang, ZH ;
Taheri, MR ;
OLeary, E ;
Li, E ;
Moskowitz, MA ;
Sapirstein, A .
NATURE, 1997, 390 (6660) :622-625
[6]   High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A(2) and a highly potent inhibitor (FPL67047XX) [J].
Cha, SS ;
Lee, D ;
Adams, J ;
Kurdyla, JT ;
Jones, CS ;
Marshall, LA ;
Bolognese, B ;
AbdelMeguid, SS ;
Oh, BH .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) :3878-3881
[7]   A NOVEL ARACHIDONIC ACID-SELECTIVE CYTOSOLIC PLA2 CONTAINS A CA2+-DEPENDENT TRANSLOCATION DOMAIN WITH HOMOLOGY TO PKC AND GAP [J].
CLARK, JD ;
LIN, LL ;
KRIZ, RW ;
RAMESHA, CS ;
SULTZMAN, LA ;
LIN, AY ;
MILONA, N ;
KNOPF, JL .
CELL, 1991, 65 (06) :1043-1051
[8]   CYTOSOLIC PHOSPHOLIPASE A(2) [J].
CLARK, JD ;
SCHIEVELLA, AR ;
NALEFSKI, EA ;
LIN, LL .
JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING, 1995, 12 (2-3) :83-117
[9]   PURIFICATION OF A 110-KILODALTON CYTOSOLIC PHOSPHOLIPASE-A2 FROM THE HUMAN MONOCYTIC CELL-LINE U937 [J].
CLARK, JD ;
MILONA, N ;
KNOPF, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (19) :7708-7712
[10]  
Connolly S., 1993, DRUG NEWS PERSPECT, V6, P584